September 25, 2013 — iCAD Inc. has announced a strategic alliance with DermEbx to offer the Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers. DermEbx currently services 14 locations in Arizona, California and Nevada with Xoft System units placed in all locations.
“DermEbx integrates the mobile Xoft System into its dermatology centers by allowing treatment to occur in the facility where the diagnosis is made, potentially eliminating the need to visit multiple service providers at different locations,” said David Berman, M.D., medical director, Berman Gladstone Skin Institute. “The mobility of the Xoft System enables a radiation oncologist to treat more patients at multiple dermatology centers.”
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized X-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs.
For more information: www.xoftinc.com, www.dermEbx.com, www.icadmed.com
April 10, 2026 
